CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
白细胞介素-1 在 CAR-T 细胞治疗中双重作用的系统综述：增强剂与缓解剂
英文原题：A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.
查看英文原题
A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是治疗某些血液系统恶性肿瘤和实体瘤的突破性方法。然而，其应用受到严重毒性的限制，尤其是CRS和ICANS，极大地限制了其更广泛的应用。IL-1在增强CAR-T 细胞疗效和驱动这些毒性效应方面均发挥关键作用。本综述系统探讨了IL-1的双重功能，重点阐述其在促进CAR-T 细胞活化和持久性方面的作用，同时参与CRS和ICANS的发病机制。减轻IL-1驱动毒性的策略，包括IL-1受体拮抗剂、单克隆抗体、IL-1捕获以及干扰IL-1产生，在减少不良反应而不影响治疗效果方面显示出前景。理解IL-1在CAR-T 细胞疗法中的复杂作用可能有助于优化治疗策略，提高安全性并扩大临床适用性。
进一步的研究对于完善IL-1靶向干预措施和增强CAR-T 细胞疗法的治疗潜力至关重要。嵌合抗原受体（CAR）T细胞疗法是治疗某些血液系统恶性肿瘤和实体瘤的突破性方法。
然而，其应用受到严重毒性的限制，尤其是细胞因子释放综合征（CRS）和细胞相关神经毒性综合征（ICANS），极大地限制了其更广泛的应用。IL-1在增强CAR-T 细胞疗效和驱动这些毒性效应方面均发挥关键作用。本综述系统探讨了IL-1的双重功能，重点阐述其在促进CAR-T 细胞活化和持久性方面的作用，同时参与CRS和ICANS的发病机制。减轻IL-1驱动毒性的策略，包括IL-1受体拮抗剂、单克隆抗体、IL-1捕获以及干扰IL-1产生，在降低不良反应的同时不影响治疗效果方面显示出前景。理解IL-1在CAR-T 细胞治疗中的复杂作用可能有助于优化治疗策略，提高安全性并扩大临床适用性。
进一步的研究对于完善IL-1靶向干预措施和增强CAR-T 细胞治疗的治疗潜力至关重要。
展开英文摘要原文
Chimeric antigen receptor T-cell therapy is a groundbreaking approach for treating certain hematologic malignancies and solid tumors.
However, its application is limited by severe toxicities, particularly CRS and ICANS, dramatically limit its broader application. IL-1 plays a crucial role in both enhancing CAR T-cell efficacy and driving these toxic effects. This review systematically examines the dual functions of IL-1, highlighting its role in promoting CAR T-cell activation and persistence while contributing to CRS and ICANS pathogenesis.
Strategies to mitigate IL-1-driven toxicities, including IL-1 receptor antagonists, monoclonal antibodies, IL-1 trapping, and interference with IL-1 production, show promise in reducing adverse effects without compromising therapeutic efficacy. Understanding the complex role of IL-1 in CAR T-cell therapy may lead to optimized treatment strategies, improving safety and expanding clinical applicability.
Further research is essential to refine IL-1-targeted interventions and enhance the therapeutic potential of CAR T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking approach for treating certain hematologic malignancies and solid tumors.
However, its application is limited by severe toxicities, particularly cytokine release syndrome (CRS) and cell-associated neurotoxicity syndrome (ICANS), dramatically limit its broader application. IL-1 plays a crucial role in both enhancing CAR T-cell efficacy and driving these toxic effects. This review systematically examines the dual functions of IL-1, highlighting its role in promoting CAR T-cell activation and persistence while contributing to CRS and ICANS pathogenesis.
Strategies to mitigate IL-1-driven toxicities, including IL-1 receptor antagonists, monoclonal antibodies, IL-1 trapping, and interference with IL-1 production, show promise in reducing adverse effects without compromising therapeutic efficacy. Understanding the complex role of IL-1 in CAR T-cell therapy may lead to optimized treatment strategies, improving safety and expanding clinical applicability.
Further research is essential to refine IL-1-targeted interventions and enhance the therapeutic potential of CAR T-cell therapy.
论文信息
- 作者
- Maali A、Noei A、Feghhi-Najafabadi S、Sharifzadeh Z
- 单位
- Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.Iran
- 文献类型
- 系统综述
- 期刊
- Iranian biomedical journal2024 Sep 1
- 原文标识
- PubMed 39891450 · DOI 10.61186/ibj.4444
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →